Is Pharming Group N.V. (PHAR) Overvalued?
We dive into why Pharming Group N.V. (PHAR) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Commentary & Analysis
Why Pharming Group N.V.’s (PHAR) Stock Is Up 6.26%
As of Tuesday, August 04, Pharming Group N.V.’s PHAR share price has surged by 6.26%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Pharming Group N.V.’s (PHAR) Stock Is Down 6.51%
As of Friday, July 31, Pharming Group N.V.’s PHAR share price has dipped by 6.51%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Pharming Group N.V.’s (PHAR) Stock Is Down 15.28%
As of Thursday, July 30, Pharming Group N.V.’s PHAR share price has dipped by 15.28%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Pharming Group N.V.’s (PHAR) Stock Is Down 17.15%
As of Thursday, July 30, Pharming Group N.V.’s PHAR share price has dipped by 17.15%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | PHAR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $839.8 | $292.6 | 42% |
|
| Shares Out (Mil) | 666.1 | 54.4 | 91% |
|
| Institutional Ownership | 93.1% | 93.2% | 62% |
|
| Float (Mil) | 696.6 | 40.2 | 88% |
|
| Beta | 0.06 | 0.94 | 8% |
|
| Avg Daily Volume (000s) | 33 | 544 | 24% |
|
| Price Change (52-week) |
(3.0%) | 59.7% | 41% |
|
| Growth | PHAR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.1% | 13.6% | 65% |
|
| Net Income (5yr) | (40.1%) | (10.1%) | 9% |
|
| EPS (5yr) | (40.8%) | 16.0% | 5 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (9.1%) | (15.6%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 3 | |
| Current EPS | $0.200 | $0.460 | $0.307 | |
| Month Ago EPS | $0.082 | $0.230 | $0.066 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.072 | $0.200 | $0.290 | |
| Year/Year Chg | 9,900% | 11,400% | 9,150% | |
| Financials | PHAR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $367 | $37 | 38% |
|
| Net Income (TTM) (Mil) | $9 | ($43) | 45% |
|
| EPS (TTM) | $0.013 | ($1.400) | 40% |
|
| Operating Cash Flow (TTM) (Mil) | $35 | ($31) | 44% |
|
| Net Cash Flow (TTM) (Mil) | ($60) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $104 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $670 | $164 | 37% |
|
| Valuation | PHAR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 31.18 | 2.83 | 97% |
|
| P/E | 911.5 | 19.6 | 100% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PHAR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.5% | 64.2% | 92% |
|
| Net Margin | 2.5% | (75.9%) | 40% |
|
| ROA | 2.1% | (47.5%) | 56% |
|
| ROE | 3.8% | (55.0%) | 42% |
|
| Liabilities to Assets | 42.2% | 29.6% | 33% |
|
| F-Score | 7 | 3 | 82% |
|
Pharming Group N.V. did not pass any screens on 8/21/2026.
